Though
remdesivir benefits
COVID-19 patients, its use in those with renal dysfunction is currently limited due to concerns about possible toxic effects of accumulated sulfobutylether-β-
cyclodextrin (SBECD) on liver and kidney. We examined renal and hepatic function for a month in renally-impaired
COVID-19 patients who were treated or not treated with
remdesivir to assess the safety of the drug. A retrospective study was performed in adult
COVID-19 patients with glomerular filtration rates of <30 ml/min/1.73 m2 at admission to a tertiary care hospital between November 2020 and March 2022. Data on serum
creatinine and liver chemistry were collected serially. A total of 101 patients with impaired renal function were analyzed, comprising 64
remdesivir-treated patients and 37 who did not receive any
antiviral agent. Although
remdesivir-treated patients were more likely to be infected with the Omicron variant (79.7% vs. 48.6%), baseline characteristics did not differ significantly between the two groups. Among patients who initially did not require dialysis, 18.4% (7/38) of
remdesivir-treated patients developed
acute kidney injury (AKI) at days 4-6, compared with 51.7% (15/29) of non-
remdesivir-treated patients. Liver injury severity worsened in 3.1% (2/64) of
remdesivir-treated patients and 5.4% (2/37) of non-
remdesivir-treated patients at days 4-6. In addition, there was no significant increase in AKI and liver injury over time in
remdesivir-treated patients, and there were no cases of discontinuation of
remdesivir due to adverse reactions. Concerns regarding the safety of SBECD should not lead to hasty withholding of
remdesivir treatment in renally-impaired
COVID-19 patients.